Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Cancer Prevention Strategies That Address the Evolutionary Dynamics of Neoplastic Cells: Simulating Benign Cell Boosters and Selection for Chemosensitivity

Carlo C. Maley, Brian J. Reid and Stephanie Forrest
Carlo C. Maley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian J. Reid
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie Forrest
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published August 2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    A schematic of the genome of a simulated cell. The placement of the loci on different chromosomes is arbitrary. All loci are effectively linked due to the asexual reproduction of neoplastic cells, but mutations affect each locus independently. In most runs of the model, each diploid cell had three loci in which a dominant mutation gave the cell a selective advantage by increasing its rate of mitosis. The cells also had two loci, which required recessive mutations in both alleles before the cell increased its rate of mitosis. Mutation of a single allele in the mutator locus increased the mutation rate of the cell, and a drug resistance locus conferred resistance to the drug associated with that locus.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    The probability of achieving a cure with a cocktail of cytotoxic drugs. The base mutation rate of the cells in the neoplasm is lowest (10-6) in the upper left-hand panel and greatest (10-5) in the lower right-hand panel. The number of drugs requiring independent mutations for resistance and the time since initiation of the neoplasm at which the therapy is applied varied within each panel. Time since initiation is measured in simulated years since the initiation of the neoplasm.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    The effect of benign cell booster therapies at 11, 22, or 33 years after the initiation of the neoplasm for mutation rates of μ = 10-6, 2 × 10-6, 4 × 10-6, and 10-5 per allele per cell division. The different types of benign cell boosters are distinguished by the type of targeted locus that had to have a wild-type allele in order for the cell to receive the benefit of the booster. Upper panels, the phenotypes of the loci could be rescued by mutations to produce the wild-type phenotype either by a back mutation or by a compensating mutation. Lower panels, mutant phenotypes could not be rescued. The neutral (cytotoxic resistance) locus could be rescued in either case, but its state had no effect on the reproduction or survival of the cells in the absence of the booster therapy.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    The frequency of the HGD cells are plotted (red) and can be seen to take over the neoplasm around time step 4,000. The “benign” cells with at least one wild-type allele in the targeted recessive locus are driven near to extinction. However, mutations at the loci can be rescued by further mutations, and so when the benign cell booster is applied at time step 8,000, benign cells emerge that outcompete the HGD cells and any cells resistant to the benign cell booster.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Cure and minimal residual disease (MRD) probabilities for “weak” benign cell boosters that only allow the benign cells to reproduce at the same but not a greater rate than the HGD cells. Large SE bars on therapies applied at 11 years are due to the fact that few cancers evolve in only 11 simulated years in 4,096 cells and so the estimates are based on only a few data points.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    A comparison of five different simulated therapies early, intermediate, and late in progression for mutation rate μ = 10-6 per allele per cell division. Minimal residual disease has been excluded from these results and so the cure rates for the benign therapies seem lower than those shown in Fig. 3.

Tables

  • Figures
  • Table 1.

    The parameters of the model and the values that were used

    ParameterValuesDescription
    Dominant loci0-6 loci (3 for therapy experiments)A mutation in either allele of these loci reduces the average cell cycle time of the cell by one-time step.
    Recessive loci1-6 loci (2 for therapy experiments)Both alleles of these loci must be mutated to reduce the average cell cycle time by one-time step.
    Mutator loci1 locusNo. of loci that when mutated increase the mutation rate of the cell.
    Mutation rate10−5, 4 × 10−6, 2 × 10−6, 10−6The base mutation rate of the cells per locus per cell division.
    Mutator factor10 or 100 (100 in experiments)Increase in the mutation rate for cells with mutator mutations (1 or 2 orders of magnitude).
    Reversible mutationsYes/noWhether a mutant phenotype can be rescued by further mutations.
    Time of chemotherapy8,000, 16,000, or 24,000 time stepsThe time step at which the cytotoxic therapy starts (∼11, 22, and 33 years after initiation).
    Follow-up time3,600 time steps5 years of follow-up after therapy to test the efficacy of the simulated treatment.
    No. of drugs (no. of drug resistance loci)1-6 drugs (loci)No. of cytotoxic drugs requiring independent mutations for resistance. There is one resistance locus per drug.
    Chemotherapy durationOne-time stepCytotoxic therapies are applied in a single time step.
    Chemotherapy efficacy1The probability a sensitive cell dies in one-time step in the presence of cytotoxins.
    Time of benign booster8,000, 16,000, or 24,000 time stepsTime at which the benign booster treatment begins.
    Benign booster duration3,600 time stepsThe benign boosters are applied over the entire duration of the follow-up (5 years).
    Benign target locusDominant, recessive, mutator, drug resistanceThe locus used by the benign cell booster to distinguish benign (wild-type at locus) from nonbenign (mutated at locus) cells.
    No. of cells in the neoplasm4,096 cellsThe simulated neoplasm consists of 4,096 cells in a 64 × 64 cell grid on the surface of a simulated tube.
    • NOTE: The model can simulate a variety of assumptions about the nature of progression and dysplasia.

  • Table 2.

    The present chance of developing high grade dysplasia

    Time since intiationMutation rate (μ)
    10−62 × 10−64 × 10−610−5
    11 years (8,000 time steps)0.07 (0.01)2.25 (0.74)15.00 (1.79)58.50 (2.46)
    22 years (16,000 time steps)2.76 (0.33)15.50 (1.81)36.25 (2.40)74.50 (2.18)
    33 years (24,000 time steps)7.72 (0.53)17.25 (1.89)44.75 (2.49)89.00 (1.56)
    • NOTE: Results are based on a neoplasm of 4,096 cells with three dominant and two recessive mutations necessary for HGD, mutation rate μ per locus per cell division, reversible mutations, and mutator phenotype increasing the mutation rate by a factor f = 100. The simulations are stochastic based on the use of a random number generator, and so there is variation in the results across runs. SEs calculated from a Bernoulli process are in parentheses. There were at least 400 runs for each parameter setting.

PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 13 (8)
August 2004
Volume 13, Issue 8
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cancer Prevention Strategies That Address the Evolutionary Dynamics of Neoplastic Cells: Simulating Benign Cell Boosters and Selection for Chemosensitivity
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cancer Prevention Strategies That Address the Evolutionary Dynamics of Neoplastic Cells: Simulating Benign Cell Boosters and Selection for Chemosensitivity
Carlo C. Maley, Brian J. Reid and Stephanie Forrest
Cancer Epidemiol Biomarkers Prev August 1 2004 (13) (8) 1375-1384;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cancer Prevention Strategies That Address the Evolutionary Dynamics of Neoplastic Cells: Simulating Benign Cell Boosters and Selection for Chemosensitivity
Carlo C. Maley, Brian J. Reid and Stephanie Forrest
Cancer Epidemiol Biomarkers Prev August 1 2004 (13) (8) 1375-1384;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Developing a Benign Cell Booster
    • Conclusions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Urinary Melatonin in Relation to Breast Cancer Risk
  • Endometrial Cancer and Ovarian Cancer Cross-Cancer GWAS
  • Risk Factors of Subsequent CNS Tumor after Pediatric Cancer
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement